Dendreon (NASDAQ: DNDN) expects the Independent Data Monitoring Committee (IDMC) to review in October 2008 the interim analysis of overall survival relating to the Company's Phase 3 IMPACT (Immunotherapy for Prostate AdenoCarcinoma Treatment). DNDN November call option implied volatility is at 164, puts are at 195; above its 26-week average of 129 according to Track Data, suggesting larger price fluctuations.
Savient Pharma (NASDAQ: SVNT) closed at $21.95 Thursday. SVNT's Puricase (treatment for refractory gout) BLA (biologics license application) filing is expected this autumn. SVNT September and October option implied volatility is at 86, December is at 82. SVNT average option implied volatility over the last 26-weeks is 79 according to Track Data, suggesting larger price movement.
Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com
Tesla Roadster sets a record -- travels 313 miles on a single charge
Cramer on BloggingStocks: China's industrial focus helps lots of U.S. names 
Why do we have a weak dollar?
